TNGX
HEALTHCARETango Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving TNGX Today?
No stock-specific AI insight has been generated for TNGX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$23.62
Fundamentals
Trading
TNGX News
20 articles- Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 4, 2026
- Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer ResultsYahoo Finance·Apr 30, 2026
- Does Erasca (ERAS) Expanding ERAS-0015 to China Recast Its Global Oncology Ambitions?Yahoo Finance·Apr 20, 2026
- Is Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines?Yahoo Finance·Apr 18, 2026
- Erasca (ERAS) Climbs 390% YTD on ‘Best-in-Class’ Potential of Cancer TreatmentYahoo Finance·Apr 17, 2026
- Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of VopimetostatYahoo Finance·Apr 15, 2026
- Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price SkyrocketsMotley Fool·Apr 8, 2026
- Stifel and Jefferies Raise Targets on Tango Therapeutics (TNGX)Yahoo Finance·Apr 6, 2026
- Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day SurgeMotley Fool·Mar 30, 2026
- Evaluating Tango Therapeutics (TNGX) Rich Valuation After Recent Share Price MomentumYahoo Finance·Mar 29, 2026
- This Stock Is Up 1,229% in Just the Past Year, But Don’t Bet Your Retirement Money on ItBarchart·Mar 26, 2026
- Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.Motley Fool·Mar 19, 2026
- Tango Therapeutics’ (TNGX) Sees Cautious Analyst Optimism Following EarningsYahoo Finance·Mar 13, 2026
- Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX)Yahoo Finance·Mar 10, 2026
- X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention247 Wall St·Mar 9, 2026
- Is Erasca (ERAS) Quietly Reframing Its RAS Strategy With Tango’s Dual-Target Trial Collaboration?Yahoo Finance·Mar 9, 2026
- Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC FilingMotley Fool·Mar 9, 2026
- Tango Therapeutics (TNGX) Valuation Check After Strong Share Price Momentum And High P/S MultipleYahoo Finance·Mar 8, 2026
- Tango Therapeutics (TNGX) Soars 52% on Buy RecoYahoo Finance·Mar 8, 2026
- TNGX Stock Hits Record High on Inking Collaboration Deal With ERASYahoo Finance·Mar 6, 2026
All 20 articles loaded
Price Data
52-Week Range
$23.62
Fundamentals
Trading
About Tango Therapeutics Inc
Tango Therapeutics Inc. is a clinical-stage biotechnology firm focused on revolutionizing cancer treatment through targeted therapies based on the principle of synthetic lethality. With a robust and diverse pipeline of innovative drug candidates, the company is poised to make significant strides in precision oncology. Tango is committed to enhancing its research capabilities through strategic partnerships with esteemed academic institutions, further solidifying its role as a leader in advancing treatment paradigms in oncology. Through its visionary approach, Tango aims to address critical unmet needs in cancer care and significantly improve patient outcomes.